NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: LINCOLN · data 2026-10-31
Lincoln Pharmaceuticals Ltd
In plain words
Price: 35.2% below its 52-week high of ₹770.
Delivery: 40.2% of traded shares were kept for delivery over the last 10 sessions, against 50.8% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹694 cr |
| Net profit (last 12 months) | ₹96 cr |
| Sales growth, 3 years (yearly) | 9.4% |
| Profit growth, 3 years (yearly) | 6.4% |
At a glance
Promoters 49.8% (unchanged in a year), pledged 0.0%, institutions 4.6%.
P/E 10.4, dividend yield 0.4%. Price relative to earnings and book value (low is cheaper, not better).
ROE 12.3%, ROCE 10.9%, operating margin 12.4%: how much profit it earns on the money it uses.
Debt/equity 0.01, Profit growth 6.4% and sales growth 9.4% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
9/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 4/30: Delivery 36.3% over the last 20 sessions vs 35.4% in the 40 before (1.03x); shares delivered per day 1x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend
- 11 Sept 26Dividend Dividend ₹1.8 (ex-date) -5.0% next session
- 12 Sept 25Dividend Dividend ₹1.8 (ex-date) -0.9% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 49.78% | 49.78% | 49.78% | 49.78% |
| Foreign institutions (FII) | 4.55% | 4.60% | 5.19% | 4.70% |
| Domestic institutions (DII) | 0.02% | 0.27% | 1.09% | 0.01% |
| Mutual funds | 0.00% | 0.00% | 0.00% | 0.00% |
| Retail investors | 24.69% | 24.35% | 23.58% | 25.10% |
| Number of shareholders | 29,272 | 29,396 | 28,303 | 31,026 |
Common questions
How much do promoters hold in Lincoln Pharmaceuticals Ltd?
Promoters held 49.78% of Lincoln Pharmaceuticals Ltd at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Lincoln Pharmaceuticals Ltd debt-free?
Its latest reported debt-to-equity ratio is 0.01, which is very low.
What is Lincoln Pharmaceuticals Ltd's P/E ratio?
About 10.4, based on the last 12 months' earnings and a price of ₹499.3 (data 2026-10-31).
What is the 52-week high and low of Lincoln Pharmaceuticals Ltd?
The 52-week high is ₹770 and the 52-week low is ₹440.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Lincoln Pharmaceuticals Ltd | ₹499.3 | ₹1,005 cr | 10.4 | — | 12.3% | 10.9% | 0.01 | -5.8% |
| Bafna Pharmaceuticals Limited | ₹447.9 | ₹1,060 cr | 136.1 | — | 12.3% | 9.2% | 0.39 | +218.1% |
| Bajaj Healthcare Ltd | ₹306.3 | ₹1,031 cr | 51.5 | 1.9 | 4.3% | 13.2% | 0.47 | -33.3% |
| Sigachi Industries Limited | ₹26.36 | ₹1,009 cr | 39.7 | — | -14.6% | 6.1% | 0.31 | -29.4% |
| Remus Pharmaceuticals Ltd. | ₹843.35 | ₹994 cr | 26.9 | 2.8 | 12.2% | 14.7% | 0.08 | +27.8% |
| Sudarshan Pharma Industries Ltd | ₹36.42 | ₹895 cr | 31.1 | 4.7 | 16.3% | 28.8% | 1.84 | +7.7% |
Compare LINCOLN with BAFNAPH in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open LINCOLN in NSE Scanner →